netFormulary
Data extracted : 08/09/2010
 Formulary Section 5: Infections
Notes:

Intravenous antibiotics are more expensive than oral equivalents and some are very expensive, they also put patients at risk of IV cannula infections. Oral antibiotics are usually fairly cheap. IM injections are rarely, if ever, indicated.

Course lengths:
Prescriptions for oral antibiotics for in-patients should be reviewed at or before five days. Prescriptions for intravenous antibiotics should be reviewed at or before 48 hours, after which the patient should be considered for an oral antibiotic, if there is an equivalent available (see IV to oral switch policy). For uncomplicated urinary tract infections, three days treatment is usually sufficient in adult women. Complicated infections require longer treatment.

When initiating therapy with agents marked with Restricted, you must seek Microbiology/Infectious Diseases advice.

The restricted antimicrobials may be prescribed without discussion with microbiology if they are being used for an approved indication as specified. Use outside these indications (and any use for some antimicrobials) requires DOCUMENTED approval from one of the medical microbiologists or Infectious Diseases Physician prior to prescribing.

 Details...
05.01 Antibacterial drugs
05.01.01 Penicillins
05.01.01.01 Benzylpenicillin and phenoxymethylpenicillin
Benzylpenicillin  (Crystapen®)
Injection
Phenoxymethylpenicillin 
Tablet
Oral Solution
05.01.01.02 Penicillinase-resistant penicillins
Flucloxacillin 
Capsule
Oral solution
Injection

Note: CSM has advised that cholestatic jaundice may occur up to several weeks after treatment with Flucloxacillin has been stopped. Administration for more than 2 weeks and increasing age are risk factors. LFT’s should be monitored where prolonged therapy is used.
05.01.01.03 Broad-spectrum penicillins
Amoxicillin 
Capsule
Oral suspension
Injection

Note: If a 3g dose of amoxicillin is required, it is recommended that 6 x 500mg capsules be supplied, to be taken with plenty of fluid over a period of about half an hour. This is considerably less expensive than the use of Amoxil 3g sachets, and less unpleasant to take.
Co-Amoxiclav 
Tablet
Soluble tablet
Oral suspension
Injection

Note: CSM has advised that cholestatic jaundice may occur either during or just after treatment with co-amoxiclav. It is more common in patients above the age of 65 years and in males. The duration of treatment should be appropriate to the indication and should not usually exceed 14 days.

For 625mg dose please prescribe as co-amoxiclav 375mg and amoxicillin 250mg as this is less expensive than the 625mg tablet.
05.01.01.04 Antipseudomonal penicillins
Restricted Drug  Piperacillin and Tazobactam  (Tazocin®)
Injection

Approved Clinical Indications:
Neutropenic sepsis in haematology patients
Pseudomonas infections (if Ceftazidime unsuitable)
Treatment of severe spontaneous bacterial peritonitis.
Late onset ventilator associated pneumonia
05.01.01.05 Mecillinams
05.01.02 Cephalosporins and other beta-lactams
05.01.02 Cephalosporins
Restricted Drug  Cefixime  (Suprax®)
Tablet
Paediatric Oral Suspension
Restricted as per GUM / Gynae PID guidance only
Restricted Drug  Cefotaxime 
Injection

Approved Clinical Indications:
Neonates only
Cefradine 
Capsule
Syrup
Restricted Drug  Ceftazidime 
Injection

Approved Clinical Indications:
Cystic fibrosis
Suspected/proven Pseudomonal infections (e.g. bronchiectasis with previous isolate)
Neutropaenic sepsis in oncology patients
Restricted Drug  Ceftriaxone 
Injection

Approved Clinical Indications:
Meningitis or intracranial sepsis
Pelvic Inflammatory Disease (stat dose for Gonococcal cover)
Acute epiglottitis
Home IV therapy for recurrent chest infections in paediatrics
Cefuroxime  (Zinacef®)
Injection
05.01.02 Other beta-lactam antibiotics
Restricted Drug  Aztreonam  (Azactam®)
Injection

Approved Clinical Indications:
Cystic fibrosis
Restricted Drug  Ertapenem  (Invanz®)
Infusion

Approved Clinical Indications:
Approval by microbiology / ID only
Restricted Drug  Meropenem  (Meronem®)
Injection

Approved Clinical Indications:
Approval by Microbiology/ID only
As part of the haematology/paediatric oncology neutropenic sepsis protocol (only in patients who are at risk of seizures from imipenem eg moderate-severe renal impairment (CrCl <20ml/min), head injury, history of seizures).
Consultant approval for cystic fibrosis
05.01.03 Tetracyclines
Demeclocycline Hydrochloride  (Ledermycin®)
Capsule
For use in SIADH only
Doxycycline 
Capsule
Dispersible Tablet
Restricted Drug  Lymecycline  (Tetralysal® 300)
Capsule
Restricted for use in dermatology
Minocycline 
Capsule
Capsule MR
For use in dermatology only
Oxytetracycline 
Tablet
For use in dermatology or on microbiology advice.
05.01.03 Tigecycline
Restricted Drug  Tigecycline  (Tygacil®)
IV infusion

Approved Clinical Indications:
Microbiology/ID approval only for multiresistant acinetobacter
and other multiresistant organisms where other options unavailable.
05.01.04 Aminoglycosides
Restricted Drug  Amikacin 
Injection

Approved Clinical Indications:
Approval by Microbiology/ID only
Gentamicin 
Injection
Intrathecal Injection (preservative free)
Neomycin Sulphate 
Tablet
For use in bowel sterilisation
Restricted Drug  Tobramycin 
Injection

Approved Clinical Indications:
Cystic fibrosis
Adult bronchiectasis
Tobramycin  (Tobi®)
Nebuliser solution
05.01.05 Macrolides
Restricted Drug  Azithromycin  (Zithromax®)
Capsule
Oral suspension

Approved Clinical Indications:
Cystic fibrosis
Chlamydial infection
Prophylaxis for terminations of pregnancy
Restricted Drug  Clarithromycin 
Tablet
Suspension

Approved Clinical Indications:
Intolerance to oral erythromycin
Paediatric CF patients
H.pylori eradication
Combination therapy for TB where there is intolerance / resistance to first line therapy.
For GU/ID use
Restricted Drug  Clarithromycin  
Injection
Change to oral erythromycin, not oral clarithromycin

Approved Clinical Indications:
If NBM / vomiting and a macrolide is indicated
Pelvic inflammatory desease (See Protocol)
Severe community aquired pneumonia (CAP)
For GU/ID use
Erythromycin 
Tablet
Oral suspension
Injection - IV is restricted for use as a pro-kinetic
05.01.06 Clindamycin
Clindamycin 
Capsule
Liquid - Named patient use
 Injection

IV Approved Clinical Indications:
Serious streptococcal soft tissue infections unresponsive to penicillins or patient is penicillin allergic
Bone and joint infections where the patient is penicillin allergic
NB: Bioavailability of oral formulation is 90%

Pseudomembranous colitis is a serious toxic effect of clindamycin
05.01.07 Some other antibacterials
05.01.07 Chloramphenicol
Restricted Drug  Chloramphenicol 
Capsule
Injection

Approved Clinical Indication:
Approval by Microbiology/ID only
05.01.07 Fusidic acid
Sodium fusidate 
Tablet
Suspension
For use in Staphylococcus aureus infections, in combination with other agents. Normally use orally.

’Restricted’ Infusion
IV Approved Clinical Indication:
Approval by Microbiology/ID only
(good oral bioavailability and IV route is irritant)
NB: Fusidic acid should not be used as a single agent
05.01.07 Vancomycin and teicoplanin
Restricted Drug  Teicoplanin  (Targocid®)
Injection

Approved Clinical Indication:
Allergy to vancomycin
Paediatric oncology
Endocarditis prophylaxis if penicillin allergic (see guideline)
Empirical therapy for sepsis associated with chronic granulomatous disease
Paediatric CF patients as per guidelines
Vancomycin 
Capsule
Injection used orally
Injection

NB:
i) Injection as per microbiology guidelines
ii) Oral preparation is restricted to use in pseudomembranous colitis as a second line agent. See guidelines on the treatment of C.difficile infection
05.01.07 Linezolid
Restricted Drug  Linezolid 
Tablet
Infusion

Approved Clinical Indications:
Approval by Microbiology/ID only
Consultant approval for cystic fibrosis

CSM advice: Full blood counts to be monitored weekly
05.01.07 Polymyxins
Colistin  (Colomycin®)
Tablet
Syrup
Injection

For bowel sterilisation. IV used for Pseudomonas
Colistin  (Promxin®)
Nebule

Nebulised solution for cystic fibrosis and neutropenic prophylaxis.
Nebuliser used for Pseudomonas
05.01.08 Sulphonamides and trimethoprim
Restricted Drug  Co-trimoxazole 
Tablet
(Forte tablet is non formulary)
Suspension
Injection

Approved Clinical Indications:
Prophylaxis and treatment of PCP
Prophylaxis and treatment of spontaneous bacterial peritonitis
Sulfadiazine 
Tablet
See BNF section 5.4.7
Trimethoprim 
Tablet
Suspension

This is the drug of choice for uncomplicated urinary tract infections in adults
05.01.09 Antituberculous drugs
Restricted Drug  Capreomycin  (Capastat®)
Injection
Restricted for use in resistant tuberculosis
Restricted Drug  Cycloserine 
Capsule
Restricted for use in resistant tuberculosis
Ethambutol Hydrochloride  (Ethambutol®)
Tablet
Isoniazid 
Tablet
Elixir
Injection
Restricted Drug  Prothionamide 
Capsule - Named patient use
Restricted for use in resistant tuberculosis
Pyrazinamide 
Tablet
Restricted Drug  Rifabutin  (Mycobutin®)
Capsule
Restricted for us in mycobacterial disease
Restricted Drug  Rifampicin 
Capsule
Syrup
Infusion

Approved Clinical Indications:
Combination therapy in TB treatment
Post-exposure prophylaxis for Meningococcal and Haemophilus influenzae B meningitis.
Approval by Microbiology/ID
NB: Rifampicin should not be used as a single agent (except in meningitis post-exposure prophylaxis above)
Rifampicin and Isoniazid  (Rifinah® 300)
Tablet
Rifampicin and Isoniazid  (Rifinah® 150)
Tablet
Rifampicin and Isoniazid  (Rimactazid® 300)
Tablet
Rifampicin and Isoniazid and Pyrazinamide  (Rifater®)
Tablet
Restricted Drug  Streptomycin Sulphate 
Injection
Restricted for use in resistant tuberculosis
05.01.10 Antileprotic drugs
Restricted Drug  Dapsone 
Tablet
Restricted to dermatology use only or on microbiology approval or GU/ID use as 2nd line agent for Pneumocystis carnii pneumonia prophylaxis
05.01.11 Metronidazole and tinidazole
Metronidazole 
Tablet
Suspension
Infusion
Suppository
Restricted Drug  Tinidazole  (Fasigyn®)
Tablet
Restricted as per GU guidelines
05.01.12 Quinolones
CSM Warning – quinolones may induce convulsions in patients with or without a history of convulsions; taking NSAID’s at the same time may also induce them. 4-quinolones may also induce tendon damage. (At the first sign of pain or inflammation treatment should be discontinued).
Restricted Drug  Ciprofloxacin 
Tablet
Suspension
Infusion

IV Approved Clinical Indication:
Approval by Microbiology/ID only
Bioavailability of the oral formulation is equivalent to IV
(therefore oral route should be used unless genuinely NBM)
City campus: As per oncology neutropenic sepsis protocol if penicillin allergic and unable to take oral medication
Levofloxacin  (Tavanic®)
Tablet
Restricted Drug  Moxifloxacin  (Avelox®)
Tablet

Approved Clinical Indication:
For multi-resistant TB or where other first line TB treatments are inappropriate
Restricted Drug  Ofloxacin 
Tablet
Restricted for treatment of pelvic inflammatory disease only
05.01.13 Urinary-tract infections
Cefradine 
See section 5.1.2
Nitrofurantoin 
Tablet
Oral suspension

NB: Avoid in renal impairment
Trimethoprim 
See section 5.1.8
05.02 Antifungal drugs
05.02 Drugs used in fungal infections
Restricted Drug  Amphotericin  (Abelcet®)
Infusion

Approve Clinical Indications:
Consultant approval for haematology patients
Critical care at city campus as per guidelines
Restricted Drug  Amphotericin  (AmBisome®)
Infusion

Approve Clinical Indications:
Consultant approval for haematology patients
Paediatric oncology
Amphotericin  (Fungilin®)
See section 12.3.2
Restricted Drug  Amphotericin  (Fungizone®)
Infusion

Approve Clinical Indications:
For intravitreal use, intrathecal and for eye/ear drop preparation only
Restricted Drug  Caspofungin  (Cancidas®)
Infusion

Approve Clinical Indications:
Consultant approval for haematology patients
Restricted Drug  Fluconazole 
Capsule
Oral suspension
Infusion

IV Approved Clinical Indication:
Haematology/oncology protocol if NBM or poorly absorbing.
Bioavailability of the oral formulation is > 90% (therefore oral route should be used unless genuinely NBM)
Restricted Drug  Flucytosine  (Ancotil®)
Infusion
Restricted for proven systemic yeast infections. Discuss with microbiologist - Serum assays required to minimise toxicity.
Restricted Drug  Griseofulvin 
Tablet
Restricted for scalp and dermatophyle infections in children
Itraconazole  (Sporanox®)
Capsule
Liquid
Miconazole  (Daktarin®)
See section 12.3.2
Nystatin  (Nystan®)
See section 12.3.2
Restricted Drug  Terbinafine 
Tablet
Restricted for use in severe tinea infections where oral therapy is appropriate
Restricted Drug  Voriconazole  (Vfend®)
Tablet
Suspension
Infusion

Approve Clinical Indications:
consultant approval for haematology / bone marrow transplant patients
ID use for HIV patients
05.03 Antiviral drugs
05.03.01 HIV infection
05.03.01 Nucleoside reverse transcriptase inhibitors
Restricted Drug  Abacavir  (Ziagen®)
Tablet
Oral Solution
Restricted to ID / GU Medicine advice only
Restricted Drug  Abacavir and Lamivudine  (Kivexa®)
Tablet
Restricted to ID / GU Medicine advice only
Restricted Drug  Abacavir and Lamivudine and Zidovudine  (Trizivir®)
Tablet
Restricted to ID / GU Medicine advice only
Restricted Drug  Didanosine  (Videx®)
Tablet
Capsule EC
Powder to make suspension is named patient
Restricted to ID / GU Medicine advice only
Restricted Drug  Emtricitabine  (Emtriva®)
Capsule
Oral Solution
Restricted to ID / GU Medicine advice only
Restricted Drug  Lamivudine  (Epivir®)
Tablet
Oral Solution
For HIV infection in combination with other antiretroviral drugs
Restricted to ID / GU Medicine advice only
Restricted Drug  Lamivudine  (Zeffix®)
Tablet
Oral Solution
For chronic hepatitis B infection
Restricted to ID / GU Medicine advice only
Restricted Drug  Stavudine  (Zerit®)
Capsule
Oral Solution
Restricted to ID / GU Medicine advice only
Restricted Drug  Tenofovir and Emtricitabine  (Truvada®)
Tablet
Restricted to ID / GU Medicine advice only
Restricted Drug  Tenofovir Disproxil  (Viread®)
Tablet
Restricted to ID / GU Medicine advice only
Restricted Drug  Zidovudine  (Retrovir®)
Capsule
Oral solution
Injection
Restricted to ID / GU Medicine and Microbiology advice only
Restricted Drug  Zidovudine and Lamivudine  (Combivir®)
Tablet
Restricted to ID / GU Medicine advice only
Restricted Drug  Zidovudine and lamivudine  (Combivir®)
Tablet
Restricted to ID / GU Medicine advice only
05.03.01 Protease inhibitors
Restricted Drug  Amprenavir  (Agenerase®)
Capsule
Oral Solution
Restricted to ID / GU Medicine advice only
Restricted Drug  Atazanavir  (Reyataz®)
Capsule
Restricted to ID / GU Medicine advice only
Restricted Drug  Fosamprenavir  (Telzir®)
Tablet
Oral Suspension
Restricted to ID / GU Medicine advice only
Restricted Drug  Indinavir  (Crixivan®)
Capsule
Restricted to ID / GU Medicine advice only
Restricted Drug  Lopinavir and Ritonavir  (Kaletra®)
Capsule
Tablet
Liquid
Restricted to ID / GU Medicine advice only
Restricted Drug  Ritonavir  (Norvir®)
Capsule
Oral Solution
Restricted to ID / GU Medicine advice only
Restricted Drug  Saquinavir  (Invirase®)
Capsule
Tablet
Restricted to ID / GU Medicine advice only
Restricted Drug  Tipranavir  (Aptivus®)
Capsule
Restricted to ID / GU Medicine advice only
05.03.01 Non-nucleoside reverse transcriptase inhibitors
Restricted Drug  Efavirenz  (Sustiva®)
Capsule
Tablet
Oral Solution
Restricted to ID / GU Medicine advice only
Restricted Drug  Nevirapine  (Viramune®)
Tablet
Suspension
Restricted to ID / GU Medicine advice only
05.03.01 Other antiretrovirals
Restricted Drug  Enfuvirtide  (Fuzeon®)
Injection
Restricted to ID / GU Medicine advice only
05.03.02 Herpesvirus infections
05.03.02.01 Herpes simplex and varicella-zoster infection
In immunocompromised patient for treatment or prophylaxis – please refer to specialist protocol or seek expert advice.
In pregnancy please seek specialist advice.
Aciclovir 
Tablet
Suspension
Injection

For Herpes Simplex and Varicella Zoster.
For Herpes infection in children.
IV - For Herpes Encephalitis, Herpes Zoster and Simplex in the immunocompromised
Restricted Drug  Valaciclovir  (Valtrex®)
Tablet

Approved Clinical Indications:
Haematology patients
Herpes Zoster
GU/ID consultant advice only
05.03.02.02 Cytomegalovirus infrection
Cidofovir  (Vistide®)
Infusion
Restricted Drug  Foscarnet Sodium  (Foscavir®)
Infusion

Approved Clinical Indications:
Consultant approval for haematology patients only
Approval by Microbiology/ID in all other cases
Restricted Drug  Ganciclovir  (Cymevene®)
Infusion

Approved Clinical Indications:
Consultant approval for haematology patients ONLY
Approval by Microbiology/ID in all other cases
Restricted Drug  Valganciclovir  (Valcyte®)
Tablet

Approved Clinical Indications:
Consultant approval for haematology patients
Renal transplant patients as per guidelines for prophylaxis
05.03.03 Viral hepatitis
Adefovir Dipivoxil  (Hepsera®)
Tablet
Also used for Lamivudine resistant hepatitis B
05.03.04 Influenza
Restricted Drug  Amantadine Hydrochloride  (Lysovir®)
Capsule
Infusion is named patient use
For use in early management / prevention of influenza A and parkinson’s disease

Infusion is restricted for chronic pain
Restricted Drug  Oseltamivir  (Tamiflu®)
Capsule
Suspension
Restricted for treatment of infulenza as per NICE guidance.
Microbiology / virology only.
05.03.05 Respiratory syncytial virus
Restricted Drug  Palivizumab  (Synagis®)
Injection
Restricted for respiratory syncytial virus (RSV) in paediatrics
Restricted Drug  Ribavirin 
Capsule
Tablet
Injection is named patient use

This drug is reserved for use in severe respiratory syncytial virus (RSV) bronchiolitis in infants, children and immunocompromised patients.
For hepatitis C infection
Restricted Drug  Ribavirin  (Virazole®)
Inhalation
This drug is reserved for use in severe respiratory syncytial virus (RSV) bronchiolitis in infants, children and immunocompromised patients.
For hepatitis C infection

Approved Clinical Indications:
Approval by microbiology / ID only

05.04 Antiprotozoal drugs
05.04.01 Antimalarials
05.04.01 Chloroquine
Chloroquine 
Tablet
Syrup
(Injection is non formulary)
05.04.01 Mefloquine
Mefloquine  (Lariam®)
Tablet
05.04.01 Primaquine
Primaquine 
Tablet - Named patient use
05.04.01 Proguanil
Proguanil Hydrochloride  (Paludrine®)
Tablet
Proguanil Hydrochloride with Atovaquone  (Malarone®)
Tablet
05.04.01 Pyrimethamine
Restricted Drug  Pyrimethamine and Dapsone 
Tablet
Restricted for ID or haematology use
Pyrimethamine with Sulfadoxine  (Fansidar®)
Tablet
05.04.01 Quinine
Quinine Dihydrochloride 
Injection
Quinine Sulphate 
Tablet
05.04.02 Amoebicides
Diloxanide Furoate  (Diloxanide®)
Tablet
Metronidazole 
See section 5.1.11
05.04.03 Trichomonacides
Metronidazole 
See Section 5.1.11
05.04.04 Antigiardial drugs
Mepacrine Hydrochloride 
Tablet is named patient use
Metronidazole 
See Section 5.1.11
05.04.05 Leishmaniacides
05.04.06 Trypanocides
05.04.07 Drugs for toxoplasmosis
Sulfadiazine 
See Section 5.1.8
05.04.08 Drugs for pneumocystis pneumonia
Atovaquone  (Wellvone®)
Suspension
Used if patient is intolerant of co-trimoxazole
Co-trimoxazole 
See Section 5.1.8
Pentamidine Isetionate  (Pantacarinat®)
Injection
Nebules
05.05 Anthelmintics
05.05.01 Drugs for threadworms
Albendazole 
Tablet is named patient use
Mebendazole 
Tablet
Suspension
05.05.02 Ascaricides
05.05.03 Drugs for tapeworm infections
05.05.04 Drugs for hookworms
05.05.05 Schistosomicides
05.05.06 Filaricides
05.05.07 Drugs for cutaneous larva migrans
05.05.08 Drugs for strongyloidiasis
 ....
 Non Formulary Items
05.03.04 - Amantadine Hydrochloride  (Symmetrel®)
05.01.04 - Amikacin  (Amikin®)
05.02 - Amphotericin  (Amphocil®)
05.01.01.03 - Ampicillin 
05.01.01.03 - Ampicillin  (Penbritin®)
05.04.01 - Artemether with lumefantrine  (Riamet®)
05.04.08 - Atovaquone  (With Proguanil Hydrochloride)
05.01.02 - Cefaclor 
05.01.02 - Cefaclor  (Distaclor®)
05.01.02 - Cefaclor  (Distaclor® MR)
05.01.02 - Cefadroxil 
05.01.02 - Cefadroxil  (Baxan®)
05.01.02 - Cefalexin 
05.01.02 - Cefalexin  (Ceporex®)
05.01.02 - Cefalexin  (Keflex®)
05.01.02 - Cefpodoxime  (Orelox®)
05.01.02 - Cefuroxime Axetil 
05.04.01 - Chloroquine  (Malarivon®)
05.04.01 - Chloroquine  (Paludrine® Avloclor)
05.01.05 - Clarithromycin  (Clarosip®)
05.01.05 - Clarithromycin  (Klaricid® XL)
05.01.10 - Clofazimine 
05.01.01.03 - Co-Fluampicil 
05.01.01.03 - Co-Fluampicil  (Magnapen®)
05.01.07 - Daptomycin 
05.01.07 - Daptomycin  (Cubicin®)
05.04.01 - Doxycycline 
05.01.03 - Doxycycline  (Vibramycin-D®)
05.03.03 - Entecavir  (Baraclude®)
05.01.05 - Erythromycin  (Erymax®)
05.01.05 - Erythromycin  (Erythrocin®)
05.01.05 - Erythromycin  (Erythromycin Ethyl Succinate)
05.01.05 - Erythromycin  (Erythromycin Lactobionate)
05.01.05 - Erythromycin  (Erythroped® A)
05.03.02.01 - Famciclovir  (Famvir®)
05.01.04 - Gentamicin  (Cidomycin®)
05.01.04 - Gentamicin  (Genticin®)
05.01.04 - Gentamicin  (Isotonic Gentamicin Injection)
05.01.02 - Imipenem with Cilastatin  (Primaxin®)
05.01.02 - Imipenem with Cilastatin (IM Injection)  (Primaxim®)
05.03.02.01 - Inosine Pranobex  (Imunovir®)
05.02 - Ketoconazole  (Nizoral®)
05.01.13 - Methenamine Hippurate  (Hiprex®)
05.01.11 - Metronidazole  (Flagyl® S)
05.01.11 - Metronidazole  (Metrolyl®)
05.01.03 - Minocycline  (Acnamino® MR)
05.01.03 - Minocycline  (Minocin® MR)
05.01.03 - Minocycline  (Sebomin® MR)
05.01.12 - Nalidixic Acid  (Uriben®)
05.03.01 - Nelfinavir  (Viracept®)
05.01.04 - Netilmicin  (Netillin®)
05.01.13 - Nitrofurantoin  (Furadantin®)
05.01.13 - Nitrofurantoin  (Macrobid®)
05.01.12 - Norfloxacin 
05.01.12 - Norfloxacin  (Utinor®)
05.05.01 - Piperazine  (Piperazine® Citrate)
05.05.01 - Piperazine  (with Sennosides)
05.01.01.05 - Pivmecillinam Hydrochloride  (Selexid®)
05.02 - Posaconazole  (Noxafil®)
05.04.01 - Proguanil Hydrochloride  (With Chloroquine)
05.04.01 - Proguanil Hydrochloride with Atovaquone  (Malarone® Raediatric)
05.04.01 - Pyrimethamine  (Darprim®)
05.01.07 - Quinupristin and dalfopristin  (Synercid®)
05.03.05 - Ribavirin  (Copegus®)
05.03.05 - Ribavirin  (Rebetol®)
05.01.09 - Rifampicin  (Rifadin®)
05.01.09 - Rifampicin  (Rimactane®)
05.04.05 - Sodium Stibogluconate  (Pentostam®)
05.01.05 - telithromycin  (Ketek®)
05.01.01.02 - Temocillin  (Negaban®)
05.01.03 - Tetracycline 
05.01.03 - Tetracycline  (Deteclo®)
05.01.01.04 - Ticarcillin  (Timentin®)
05.04.02 - Tinidazole 
05.03.04 - Zanamivir  (Relenza®)